Lbp Am Sa Buys Shares of 15,629 Insulet Corporation $PODD

Key Points

• Lbp Am Sa has acquired 15,629 shares of Insulet Corporation, amounting to a total investment of approximately $4.91 million.
• Insulet reported $1.17 EPS for the last quarter, surpassing estimates of $0.92 and marking a 32.9% year-over-year revenue growth to $649.1 million.
• Corporate insiders, including SVP Prem Singh and Laetitia Cousin, have recently sold shares, with Singh selling 687 shares for about $238,725.

Lbp Am Sa purchased a new position in Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 15,629 shares of the medical instruments supplier's stock, valued at approximately $4,910,000.

Other hedge funds have also modified their holdings of the company. Larson Financial Group LLC increased its stake in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Insulet in the first quarter worth $26,000. SouthState Corp increased its stake in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new position in shares of Insulet in the second quarter worth $32,000. Finally, Ramirez Asset Management Inc. acquired a new position in shares of Insulet in the first quarter worth $53,000.

Insulet Stock Down 0.9%

PODD stock opened at $305.98 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The company has a 50-day moving average of $320.45 and a two-hundred day moving average of $297.85. The stock has a market capitalization of $21.54 billion, a price-to-earnings ratio of 93.00, a price-to-earnings-growth ratio of 2.56 and a beta of 1.40.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same period in the prior year, the company earned $0.55 earnings per share. The business's quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Transactions at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on PODD shares. Canaccord Genuity Group upped their price target on shares of Insulet from $353.00 to $399.00 and gave the stock a "buy" rating in a research note on Monday. Wells Fargo & Company upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Citigroup reiterated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Oppenheimer upped their price objective on shares of Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a report on Monday, September 8th. Finally, Piper Sandler upped their price objective on shares of Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and a consensus price target of $345.47.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.